04-05-2017 дата публикации
Номер: US20170119732A1
Автор:
Thomas A. Mustoe,
Peter Kim,
Jason Ko,
Xianzhong Ding,
Yanan Zhao,
MUSTOE THOMAS A,
KIM PETER,
KO JASON,
DING XIANZHONG,
ZHAO YANAN,
Mustoe Thomas A.,
Kim Peter,
Ko Jason,
Ding Xianzhong,
Zhao Yanan
Принадлежит:
Provided herein are compositions and methods for preventing or reducing scar formation (e.g., hypertrophic scars). Certain embodiments provide a method of preventing hypertrophic scar formation in a subject comprising administering a HMG-CoA reductase-inhibiting agent to a wound site. In some embodiments, the wound site comprises scar tissue. 1. A method for treating a subject comprising: administering a HMG-CoA reductase-inhibiting agent locally to a wound site.2. The method of claim 1 , wherein said wound site comprises scar tissue.3. The method of claim 1 , wherein said wound site does not comprise scar tissue.4. The method of claim 1 , wherein said HMG-CoA reductase-inhibiting agent comprises a statin.5. The method of claim 4 , wherein said statin is selected from the group consisting of Atorvastatin claim 4 , Cerivastatin claim 4 , Fluvastatin claim 4 , Lovastatin claim 4 , Mevastatin claim 4 , Pitavastatin claim 4 , Pravastatin claim 4 , Rosuvastatin claim 4 , and Simvastatin.6. The method of claim 1 , wherein said administering occurs by local injection.7. The method of claim 1 , further comprising administering an agent selected from the group consisting of corticosteroids claim 1 , interferon claim 1 , 5-fluorouracil claim 1 , doxorubicin claim 1 , bleomycin claim 1 , verapamil claim 1 , retinoic acid claim 1 , imiquimod claim 1 , tamoxifen claim 1 , tacrolimus claim 1 , botulinum toxin claim 1 , onion extract claim 1 , hydrocortisone claim 1 , silicone claim 1 , vitamin E claim 1 , TGF-beta claim 1 , TGF-beta1 claim 1 , TGF-beta2 claim 1 , TGF-beta3 claim 1 , VEGF inhibitors claim 1 , etanercept claim 1 , mannose-6-phosphate inhibitors claim 1 , recombinant human interleukin-10 claim 1 , proline-cis-hydroxyproline claim 1 , azetidine carboxylic acid claim 1 , tranilast claim 1 , pentoxifylline claim 1 , an anti-TGF agent claim 1 , and Gentian violet.8. The method of claim 1 , further comprising administering an additional treatment selected from the group ...
Подробнее